Hassan Ibrahim, MD
Cardiovascular Disease · Sandusky, OHNPI 1326027442
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $118,328 of the $139,885 with a category attached, or 84.6%. 22 manufacturers reported payments, led by Johnson & Johnson at 54.6% of the total. Reporting peaked in 2019 at $61,929 and has fallen 98.7% since, to $795 in 2025. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $613.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$76K
- Esperion Therapeutics, Inc.$32K
- Novartis$13K
- AstraZeneca$10K
- E.r. Squibb & Sons, L.L.C.$4K
- Pfizer$3K
- plus $2K from 16 others
Across 28 payments — averaging $10,204 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$249K
- Janssen Research & Development, LLC$30K
- GSK$6K
What the payments were for
- Consulting fees$9,0506%
- Speaking & faculty fees$118,32885%
- Travel & lodging$6,2504%
- Food & beverage$6,0154%
- Education$2410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 86 | $76,317 |
| Esperion Therapeutics, Inc. | 47 | $31,619 |
| Novartis | 23 | $12,910 |
| AstraZeneca | 16 | $10,076 |
| E.r. Squibb & Sons, L.L.C. | 25 | $3,873 |
| Pfizer | 6 | $3,416 |
| Medtronic | 1 | $633 |
| Abbott | 3 | $253 |
| Heartflow, Inc. | 1 | $140 |
| Amgen | 7 | $126 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| Actelion Pharmaceuticals US, Inc. | 1 | $120 |
| Astellas Pharma US Inc | 1 | $99 |
| Sanofi | 1 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $28 |
| CSL Behring | 1 | $25 |
| Boehringer Ingelheim | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$139,885 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 735 | $958,124 |
| XareltoRivaroxaban | 478 | $555,956 |
| EntrestoSacubitril/Valsartan | 147 | $231,329 |
| JardianceEmpagliflozin | 93 | $98,943 |
| Repatha SureclickEvolocumab | 76 | $96,862 |
| Repatha SyringeEvolocumab | 57 | $52,684 |
| Dofetilide | 233 | $46,808 |
| BrilintaTicagrelor | 27 | $30,758 |
| MultaqDronedarone Hcl | 19 | $23,374 |
| Flecainide Acetate | 354 | $20,235 |
| Ezetimibe | 545 | $17,076 |
| Praluent PenAlirocumab | 14 | $16,383 |
| Valsartan | 491 | $15,081 |
| Atorvastatin Calcium | 1,114 | $14,146 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $13,815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $3,416 | $958,124735 claims |
| Johnson & JohnsonXarelto | $76,317 | $555,956478 claims |
| NovartisEntresto | $12,910 | $231,329147 claims |
| Boehringer IngelheimJardiance | $21 | $98,94393 claims |
| AstraZenecaBrilinta | $10,076 | $30,75827 claims |
| Sanofi-aventis U.S. LLCMultaq | $15 | $23,37419 claims |
| Esperion Therapeutics, Inc.Nexlizet | $31,619 | $13,81512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Sandusky
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
- Jayanta MukherjeeColumbus$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.